EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 474 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Low-Pass Genomic Instability Characterisation Assay Identifies Germline Mismatch Repair Deficiency and... October 20, 2022 Larger NGS Gene Panel Linked to More Clinical Utility October 16, 2020 Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... June 10, 2025 Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian September 4, 2026 Load more HOT NEWS ‘A significant step forwards’ – treating patients with advanced biliary tract... Colon capsule endoscopy – reshaping bowel cancer diagnosis Improving cancer care for the LGBTQ+ community ΚΑΡΚΙΝΟΣ ΤΩΝ ΟΣΤΩΝ
